PL2310043T5 - Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów - Google Patents

Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów

Info

Publication number
PL2310043T5
PL2310043T5 PL09777111.7T PL09777111T PL2310043T5 PL 2310043 T5 PL2310043 T5 PL 2310043T5 PL 09777111 T PL09777111 T PL 09777111T PL 2310043 T5 PL2310043 T5 PL 2310043T5
Authority
PL
Poland
Prior art keywords
von willebrand
factor
willebrand factor
thrombocytes
inhibitors
Prior art date
Application number
PL09777111.7T
Other languages
English (en)
Polish (pl)
Other versions
PL2310043T3 (pl
Inventor
Gerhard Dickneite
Ingo Pragst
Henrique Lessa
Thorsten Haas
Stefan Zeitler
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2310043(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2310043T3 publication Critical patent/PL2310043T3/pl
Publication of PL2310043T5 publication Critical patent/PL2310043T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09777111.7T 2008-07-10 2009-07-10 Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów PL2310043T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP09777111.7A EP2310043B2 (en) 2008-07-10 2009-07-10 Factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (2)

Publication Number Publication Date
PL2310043T3 PL2310043T3 (pl) 2013-02-28
PL2310043T5 true PL2310043T5 (pl) 2024-02-05

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09777111.7T PL2310043T5 (pl) 2008-07-10 2009-07-10 Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów

Country Status (13)

Country Link
US (2) US8603979B2 (enExample)
EP (1) EP2310043B2 (enExample)
JP (1) JP5653916B2 (enExample)
KR (1) KR20110043654A (enExample)
CN (1) CN102088999A (enExample)
AU (1) AU2009268289B2 (enExample)
CA (1) CA2730290C (enExample)
DE (1) DE102008032361A1 (enExample)
DK (1) DK2310043T4 (enExample)
ES (1) ES2395855T5 (enExample)
PL (1) PL2310043T5 (enExample)
RU (1) RU2563236C2 (enExample)
WO (1) WO2010003687A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AU2008345135C1 (en) 2007-12-28 2015-04-30 Takeda Pharmaceutical Company Limited Recombinant VWF formulations
EP2300497B1 (en) * 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN103919736A (zh) 2008-10-21 2014-07-16 巴克斯特国际公司 冻干的重组vwf配方
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
DE60042171D1 (de) † 1999-12-24 2009-06-18 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
DK2310043T4 (da) 2022-06-20
PL2310043T3 (pl) 2013-02-28
US9095564B2 (en) 2015-08-04
US20140128325A1 (en) 2014-05-08
JP2011527301A (ja) 2011-10-27
AU2009268289A1 (en) 2010-01-14
CN102088999A (zh) 2011-06-08
US8603979B2 (en) 2013-12-10
EP2310043A1 (en) 2011-04-20
AU2009268289B2 (en) 2014-11-06
US20110112023A1 (en) 2011-05-12
CA2730290A1 (en) 2010-01-14
DK2310043T3 (da) 2013-01-07
ES2395855T5 (es) 2022-09-06
RU2563236C2 (ru) 2015-09-20
WO2010003687A1 (en) 2010-01-14
CA2730290C (en) 2017-02-07
EP2310043B2 (en) 2022-05-18
DE102008032361A1 (de) 2010-01-21
JP5653916B2 (ja) 2015-01-14
EP2310043B1 (en) 2012-09-19
KR20110043654A (ko) 2011-04-27
RU2011104705A (ru) 2012-08-20
ES2395855T3 (es) 2013-02-15

Similar Documents

Publication Publication Date Title
PL2310043T3 (pl) Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów
ATE550333T1 (de) 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
EP2313146A4 (en) DEVICES FOR TREATING VASCULAR ANEVRYSM
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
EP4091585C0 (en) DEVICE FOR TREATMENT OF PATHOLOGICAL GASTRO-SOPHAGEAL REFLUX
EP2200649A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
BRPI0905738A2 (pt) "conjunto de um recipiente e um fecho e fecho"
IL212250A0 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
EP2271218A4 (en) USE AND COMPOSITION FOR THE TREATMENT OF DEMENTIA
EP2386616A4 (en) ADHESIVE ADHESIVE FOR POLARIZER AND POLARIZER MANUFACTURED THEREOF
EP2349310A4 (en) POLYPEPTIDE FOR TREATING OR PREVENTING ADHESIONS
EP2855500A4 (en) METHOD AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
BRPI0905740A2 (pt) "fecho e recipiente"
BRPI0907146A2 (pt) recipiente plástico de uma peça e método de fazer o mesmo
EP2579936A4 (en) INTRAGASTRIC DEVICE FOR TREATING OBESITY
ATE525904T1 (de) Behandlung von bananen
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
EP2834329A4 (en) SUCCINIMIDACTIVED NITROXYL COMPOUNDS AND METHOD FOR USE THEREOF FOR NITROXYLATION OF PROTEINS
EP2520278A4 (en) MEANS FOR REMOVAL OF TOBACCO TAR AND COMPOSITION CONTAINING THESE MEANS
EP2193373A4 (en) METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
AT509344A5 (de) Vorrichtung zum gesteuerten auslösen von lawinen